TCGA-CV-A6JD-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.041552511
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.570
- INTERFERON_GAMMA_RESPONSE+0.470
- DNA_REPAIR+0.420
- TNFA_SIGNALING_VIA_NFKB+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- ALLOGRAFT_REJECTION+0.350
- P53_PATHWAY+0.350
- ANGIOGENESIS+0.340
- OXIDATIVE_PHOSPHORYLATION+0.330
- NOTCH_SIGNALING+0.320
Top 10 suppressed
- G2M_CHECKPOINT-0.500
- E2F_TARGETS-0.400
- MITOTIC_SPINDLE-0.350
- ESTROGEN_RESPONSE_EARLY-0.290
- MTORC1_SIGNALING-0.270
- KRAS_SIGNALING_DN-0.260
- CHOLESTEROL_HOMEOSTASIS-0.240
- ESTROGEN_RESPONSE_LATE-0.240
- PROTEIN_SECRETION-0.210
- ANDROGEN_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8942960 | — | — | 0.794 |
| 2 | 56c90a71-00af-4e8a-a75d-01a39d44d1f3 | — | — | 0.766 |
| 3 | TCGA-XF-A9SX-01A-21R-A39I-07 | — | — | 0.761 |
| 4 | 706B5E97-06B6-4401-9934-7CF12FF7F816 | — | — | 0.757 |
| 5 | 21f65654-07a2-4b27-b511-2497fa298d0e | — | — | 0.741 |
| 6 | GSM5359420 | — | — | 0.740 |
| 7 | BS_2W3NC4K1 | Neurofibroma | — | 0.731 |
| 8 | BS_3Y0QXZQB | Neurofibroma | — | 0.727 |
| 9 | MNG900 | — | — | 0.723 |
| 10 | BS_893A91ZM | Neurofibroma | — | 0.722 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |